HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations : Episode 11
Opinion
Video
Real-World Outcomes in HER2-Positive NSCLC
Key Takeaways
- Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment settings.
- Clinical trials involve selected patients, while real-world settings include those with comorbidities and varying performance statuses.
Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Video content above is prompted by the following:
- How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Related Videos
Related Content
